Assessment of the relationship between treatment response (EASI75) and change in quality of life (EQ-5D) by week 24.

Description of the:

• Change in disease activity after 16 and 24 weeks
• Change in subject and family quality of life after 16 and 24 weeks
• Change in sleep quality after 16 and 24 weeks
• Change in anxiety after 16 and 24 weeks
• Change in depression after 16 and 24 weeks
• Safety and tolerability

28 weeks

Inclusion Criteria:

• Patient eligible for Dupixent therapy of AD according to the current SPC and reimbursement criteria given by the SUKL
• Signed informed consent
• 18 years and older (study questionnaires are validated for this age group). Patient is able to follow the prescribed regimen, routine follow-up visits and to fill the questionnaires

Exclusion Criteria:

- Patient not eligible for Dupixent therapy of AD according to the current SPC and reimbursement criteria given by the SUKL.

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Patients eligible for Dupixent therapy of atopic dermatitis (AD) according to the current summary of product characteristics (SPC) and reimbursement criteria given by the State Institute for Drug Control (SUKL) in Czech Republic

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org